Launching New Drugs in the Time of COVID-19

October 7, 2020 12:00 PM - 1:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 10/7/2020 12:00:38 PM 10/7/2020 1:00:38 PM Launching New Drugs in the Time of COVID-19

Did you know that since the onset of COVID-19 at the end of March of this year the FDA has approved over 18 novel drugs, six of which were for biotech companies based in Massachusetts or with facilities in the Bay State? How are companies taking on the extraordinary challenges and obstacles of launching (or choosing not to launch) new drugs in the time of COVID-19? How are they educating and communicating with the audiences and stakeholders that are impacted?

This panel will be moderated by Business Insider Pharma Industry Reporter Andrew Dunn and will include executives from Bristol Myers Squibb and Sanofi exploring the approaches their companies have taken when it comes to launching newly approved drugs and how they’ve balanced all the competing needs and demands involved.

Sponsored by the MassBio MarComm and Commercial forum working group.

MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

 Webinar, click "live-stream" button to view
General Manager, Head of US Oncology, Sanofi Genzyme
Chris Sarchi is General Manager, Head of US Oncology at Sanofi Genzyme and is responsible for marketing and commercialization of Oncology products for the U.S. market. Since he joined, the team has successfully launched two new products in two years, setting the stage for an anticipated 13 new product approvals or line extensions over the next five years. Chris joined Sanofi Genzyme in December 2017, continuing a successful career in the pharmaceutical and biotechnology industry for more than 28 years, with 26 year focusing on the Oncology space. During this time, he held various leadership positions in sales, marketing, strategic planning and new product development, as well as business unit leadership. Prior to his current role, Chris was the VP & BU Head of Oncology and Biosimilars at Boehringer Ingelheim from 2013-2018. At BI, Chris was responsible for the initial build out of the oncology field commercial team. Chris has had additional leadership opportunities and experiences during his time at GSK, as well as Roche/Genentech.